Has Johnson Haynes received payments from drug or device companies?

Yes. Drug and device makers reported $21,375 in general payments to Johnson Haynes across 78 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Johnson Haynes did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Johnson Haynes come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Johnson Haynes

Pulmonary Disease · Mobile, ALNPI 1760437800

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,463 of the $21,375 with a category attached, or 86.4%. Global Blood Therapeutics, Inc. accounts for 80.3% of it on its own, with 16 other manufacturers making up the rest. Among pulmonary disease clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,375in general payments, 2019–2025

Across 78 payments — averaging $274.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Global Blood Therapeutics, Inc.$17K
Novartis$3K
Johnson & Johnson$239
Astellas Pharma US Inc$94
Pfizer$83
Actelion Pharmaceuticals US, Inc.$83
plus $281 from 11 others

$28,878in research payments, 2019–2025

Across 21 payments — averaging $1375.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$16K
Global Blood Therapeutics, Inc.$13K

What the payments were for

Speaking & faculty fees$18,46386%
Travel & lodging$1,3416%
Food & beverage$1,5397%
Education$320%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Global Blood Therapeutics, Inc.	24	$17,169
Novartis	13	$3,425
Johnson & Johnson	14	$239
Astellas Pharma US Inc	5	$94
Pfizer	1	$83
Actelion Pharmaceuticals US, Inc.	3	$83
Emmaus Medical, Inc.	2	$38
E.r. Squibb & Sons, L.L.C.	3	$38
Bayer	2	$34
Novo Nordisk	1	$32
AstraZeneca(2 entities)	2	$31
Sunovion Pharmaceuticals Inc.	2	$29
Philips North America LLC	2	$27
Sanofi Pasteur Inc.	1	$14
Sanofi	1	$14
Sandoz	1	$12
Covidien LP	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OXBRYTA$12,871
ADAKVEO$2,444

How this compares

$21,375 in reported general payments places this provider in the 90th percentile of 215 pulmonary disease providers in Alabama.

See all pulmonary disease providers in Alabama →

Other pulmonary disease in Mobile

Adrian DivittorioMobile$100K
Peter LutzMobile$63K
Virginia RadcliffMobile$23K
Cynthia CrowderMobile$20K
Philip AlmaloufMobile$14K
Campbell SindelMobile$14K
Chibuzo OdigweMobile$14K
Caesar AgaganMobile$11K
James DeanMobile$10K
Maher SahawnehMobile$9K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →